Department of Hematology, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.
Department of Neuro-oncology, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.
Rev Invest Clin. 2021 Apr 12;73(4):231-237. doi: 10.24875/RIC.21000010.
Central nervous system international prognosis index (CNS-IPI) is validated in European and the USA cancer databases. However, no validation has been done in Mexican population.
The objective of the study was to assess the impact of the CNS-IPI on central nervous system (CNS) relapse and survival in Mexican patients with diffuse large B-cell lymphoma (DLBCL).
In this retrospective analysis, clinical, biochemical, and histological variables and the CNS-IPI were analyzed.
Six hundred and forty-two patients with DBLCL were included in the study. The mean ± SD age was 56.8 ± 14.9 years. Most had an ECOG of 0-1: 75% (n = 484) had absence of B-symptoms and advanced disease (clinical stage: III-IV, n = 433, 67.4%). According to the CNS-IPI, almost one-half were in the low-risk category. According to the CNS-IPI, CNS relapse rate was 1.36% (95% CI: 83.2-92.8), 3.1% (95% CI: 132.4-162.8), and 7.4% (95% CI 61-91) for patients in the low-, intermediate-, and high-risk categories, respectively. The median overall survival in the high-risk group (CNS-IPI) was 22 months, and it has not been achieved after 80 months of follow-up for the other groups.
CNS-IPI was associated with survival; therefore, we propose its use as a prognostic tool for prospective validation.
中枢神经系统国际预后指数（CNS-IPI）已在欧洲和美国的癌症数据库中得到验证。然而，尚未在墨西哥人群中进行验证。
本研究旨在评估 CNS-IPI 对墨西哥弥漫性大 B 细胞淋巴瘤（DLBCL）患者中枢神经系统（CNS）复发和生存的影响。
在这项回顾性分析中，分析了临床、生化和组织学变量以及 CNS-IPI。
本研究纳入了 642 例 DLBCL 患者。平均年龄 ± 标准差为 56.8 ± 14.9 岁。大多数患者的 ECOG 评分为 0-1：75%（n = 484）无 B 症状且疾病处于晚期（临床分期：III-IV 期，n = 433，67.4%）。根据 CNS-IPI，近一半患者属于低危类别。根据 CNS-IPI，低危、中危和高危患者的 CNS 复发率分别为 1.36%（95%CI：83.2-92.8）、3.1%（95%CI：132.4-162.8）和 7.4%（95%CI 61-91）。高危组（CNS-IPI）的中位总生存期为 22 个月，而其他组在 80 个月的随访后尚未达到。
CNS-IPI 与生存相关；因此，我们建议将其作为一种预后工具进行前瞻性验证。
